Mustang Bio (MBIO) Asset Writedowns and Impairment (2024)
Mustang Bio (MBIO) posted quarterly Asset Writedowns and Impairment of $1.0 million for Q4 2024, down 59.88% quarter-over-quarter from $2.6 million in Q2 2024.
Mustang Bio (MBIO) Asset Writedowns and Impairment (2024) Analysis & Trends
Mustang Bio (MBIO) has reported Asset Writedowns and Impairment for 1 consecutive years, with $1.0 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Asset Writedowns and Impairment changed N/A year-over-year to $1.0 million; the TTM figure through Dec 2025 stood at $1.0 million (down 71.37% YoY), while the FY2024 annual figure was $3.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment eased to $1.0 million in Q4 2024 per MBIO's latest filing, from $2.6 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $2.6 million in Q2 2024 and bottomed at $1.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1.04 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Jun 30, 2024 | 2.60 Mn |
| Jun 30, 2024 | 2.60 Mn |